Gioffredi A, Maritati F, Oliva E, Buzio C. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immuno Published Online. 2014;5:549. https://doi.org/10.3389/fimmu.2014.00549.

CAS  Article  Google Scholar 

Fagni F, Bello F, Emmi G. Eosinophilic granulomatosis: dissecting the pathophysiology. Front Med. 2021. https://doi.org/10.3389/fmed.2021.627776.

Article  Google Scholar 

• Lyons PA, Peters JE, Alberici F, Liley J, Coulson RMR, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10(1):5120. https://doi.org/10.1038/s41467-019-12515-9. COMMENT: Study showing genetic differences in ANCA-positive and ANCA-negative eGPA.

Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015;126(9):1069–77. https://doi.org/10.1182/blood-2014-11-551614.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy. 2013;68:261–73. https://doi.org/10.1111/all.12088.

CAS  Article  PubMed  Google Scholar 

•• Wechsler ME, Akuthota P, Jayne D, Khoury P, Kilon CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932. COMMENT: Study that led to FDA approval for mepolizumab use in eGPA.

Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–66. https://doi.org/10.1056/nejmoa1304048.

CAS  Article  PubMed  Google Scholar 

Eger K, Pet L, Weersink EJ, Bel EH. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract. 2021;9(7):2913–5. https://doi.org/10.1016/j.jaip.2021.02.042.

CAS  Article  PubMed  Google Scholar 

Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.

CAS  Article  Google Scholar 

Isozaki T, Homma T, Sagara H, Kasama T. Role of cytokines in eGPA and the possibility of treatment with an anti-IL-5 antibody. J Clin Med. 2020;9:3890. https://doi.org/10.3390/jcm9123890.

CAS  Article  PubMed Central  Google Scholar 

Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int. 2020;69:178–86. https://doi.org/10.1016/j.alit.2020.02.002.

CAS  Article  PubMed  Google Scholar 

Radonjic-Hoseli S, Valent P, Kilon AD, Wechsler ME, Simon H. Novel targeted therapies for eosinophilic-associated diseases and allergy. Annu Rev Pharmacol Toxicol. 2015;55:633–56. https://doi.org/10.1146/annurev-pharmtox-010814-124407.

CAS  Article  Google Scholar 

Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manag. 2018;14:2385–96. https://doi.org/10.2147/tcrm.s159949.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Guntur VP, Manka LA, Denson JL, Dunn RM, Dollin YT, Gill M, Kolakowski C, Strand MJ, Wechsler ME. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2021;9(3):1186-1193.e1. https://doi.org/10.1016/j.medcli.2021.07.017.

CAS  Article  PubMed  Google Scholar 

Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;1–18. https://doi.org/10.1002/art.41773.

CAS  Article  Google Scholar 

Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.00888.

Article  PubMed  PubMed Central  Google Scholar 

Xiaojing M. (ed). Regulation of cytokine gene expression in immunity and diseases. In: Advances in experimental medicine and biology. 1st ed. Springer Dordrecht; 2016; p. 941. ISBN: 978–94–024–0919–2. https://doi.org/10.1007/978-94-024-0921-5

Toru H, Ra C, Nonoyama S, Suzuki K, Yata J, Nakahata T. Induction of the high-affinity IgE receptor (FceRI) on human mast cells by IL-4. Int Immunol. 1996;8(9):1367–73. https://doi.org/10.1093/intimm/8.9.1367.

CAS  Article  PubMed  Google Scholar 

May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. 2015;75(1):89–116. https://doi.org/10.1016/j.cyto.2015.05.018.

CAS  Article  PubMed  Google Scholar 

Walter DM, McIntire JJ, Berry G, McKenzie ANJ, Donaldson DD, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol. 2001;167(8):4668–75. https://doi.org/10.4049/jimmunol.167.8.4668.

CAS  Article  PubMed  Google Scholar 

Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761055s020lbl.pdf. Accessed 10 July 2021.

Hogan SP, Mould A, Kikutani H, Ramsay AJ, Foster PS. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest. 1997;99(6):1329–39. https://doi.org/10.1172/jci119292.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, Foster PS. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol. 2000;165(1):108–13. https://doi.org/10.4049/jimmunol.165.1.108.

CAS  Article  PubMed  Google Scholar 

Kariyawasam HH, James LK, Gane SB. Dupilumab: clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020;14:1757–69. https://doi.org/10.2147/DDDT.S243053.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–50. https://doi.org/10.1016/s0140-6736(19)31881-1.

CAS  Article  PubMed  Google Scholar 

Menzella F, Montanari G, Patricelli G, Cavazza A, Galeone C, Ruggiero P, Bagnasco D, Facciolongo N. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag. 2019;15:869–75. https://doi.org/10.2147/tcrm.s207402.

Article  PubMed  PubMed Central  Google Scholar 

Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68(4):430–6. https://doi.org/10.1016/j.alit.2019.06.004.

CAS  Article  PubMed  Google Scholar 

Moon BG, Takaki S, Miyake K, Takatsu K. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol. 2004;172(10):6020–9. https://doi.org/10.4049/jimmunol.172.10.6020.

CAS  Article  PubMed  Google Scholar 

Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018;5:49. https://doi.org/10.3389/fmed.2018.00049.

Article  Google Scholar 

Hajoui O, Janani R, Tulic M, Joubert P, Ronis T, et al. Synthesis of IL-13 by human B lymphocytes: regulation and role in IgE production. J Allergy Clin Immunol. 2004;114(3):657–63. https://doi.org/10.1016/j.jaci.2004.05.034.

CAS  Article  PubMed  Google Scholar 

McLeod JJ, Baker B, Ryan JJ. Mast cell production and response to IL-4 and IL-13. Cytokine. 2015;75(1):57–61. https://doi.org/10.1016/j.cyto.2015.05.019.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Angkasekwinai P, Sodthawon W, Jeerawattanawart S, Hansakon A, Pattanapanyasat K, et al. ILC2s activated by IL-25 promote antigen-specific Th2 and Th9 functions that contribute to the control of Trichinella spiralis infection. PLoS ONE. 2017;12(9): e0184684. https://doi.org/10.1371/journal.pone.0184684.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Liu D, Cao T, Wang N, Liu C, Ma N, et al. IL-25 attenuates rheumatoid arthritis through suppression of Th17 immune responses in an IL-13-dependent manner. Sci Rep. 2016;6:36002. https://doi.org/10.1038/srep36002.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Shao Z, Shangguan G, Bie Q, Zhang B. Biological properties and the role of IL-25 in disease pathogenesis. J Immunol Res. 2018;2018:6519465. https://doi.org/10.1155/2018/6519465.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Valizadeh A, Khosravi A, Zadeh LJ, Parizad EG. Role of IL-25 in immunity. J Clin Diagn Res. 2015;9(4):OE01-OE4. https://doi.org/10.7860/jcdr/2015/12235.5814.

Article  PubMed  PubMed Central  Google Scholar 

Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, et al. Interleukin-13 in asthma and other eosinophilic disorders. Front Med (Lausanne). 2017;4:139. https://doi.org/10.3389/fmed.2017.00139.

Article  Google Scholar